GEAP202416425A - Imidazole-containing inhibitors of alk2 kinase - Google Patents

Imidazole-containing inhibitors of alk2 kinase

Info

Publication number
GEAP202416425A
GEAP202416425A GEAP202416425A GEAP2024016425A GEAP202416425A GE AP202416425 A GEAP202416425 A GE AP202416425A GE AP202416425 A GEAP202416425 A GE AP202416425A GE AP2024016425 A GEAP2024016425 A GE AP2024016425A GE AP202416425 A GEAP202416425 A GE AP202416425A
Authority
GE
Georgia
Prior art keywords
iii
imidazole
pharmaceutically acceptable
compounds
alk2 kinase
Prior art date
Application number
GEAP202416425A
Other languages
English (en)
Georgian (ka)
Inventor
Yarlagadda S Babu
Pravin L Kotian
Krishnan Raman
Andrew E Spaulding
peng-cheng Lu
Wei Lv
Weihe Zhang
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of GEAP202416425A publication Critical patent/GEAP202416425A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GEAP202416425A 2021-05-25 2022-05-24 Imidazole-containing inhibitors of alk2 kinase GEAP202416425A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163192822P 2021-05-25 2021-05-25

Publications (1)

Publication Number Publication Date
GEAP202416425A true GEAP202416425A (en) 2024-02-12

Family

ID=84230377

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416425A GEAP202416425A (en) 2021-05-25 2022-05-24 Imidazole-containing inhibitors of alk2 kinase

Country Status (23)

Country Link
US (1) US20240270750A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346806A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520359A (cg-RX-API-DMAC7.html)
KR (1) KR20240013145A (cg-RX-API-DMAC7.html)
CN (1) CN117529315A (cg-RX-API-DMAC7.html)
AR (1) AR125963A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022283258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024537A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219966A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003503A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230597A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000254A (cg-RX-API-DMAC7.html)
EC (1) ECSP23096182A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416425A (cg-RX-API-DMAC7.html)
IL (1) IL308513A (cg-RX-API-DMAC7.html)
JO (1) JOP20230303A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013742A (cg-RX-API-DMAC7.html)
PE (1) PE20250022A1 (cg-RX-API-DMAC7.html)
PY (1) PY2240952A (cg-RX-API-DMAC7.html)
TW (1) TW202313625A (cg-RX-API-DMAC7.html)
UY (1) UY39788A (cg-RX-API-DMAC7.html)
WO (1) WO2022251188A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
BR0111754A (pt) * 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
JP2012504157A (ja) * 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CN108239071B (zh) * 2016-12-27 2020-12-04 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見

Also Published As

Publication number Publication date
BR112023024537A2 (pt) 2024-02-06
UY39788A (es) 2023-01-31
JP2024520359A (ja) 2024-05-24
IL308513A (en) 2024-01-01
PY2240952A (es) 2022-12-26
EP4346806A2 (en) 2024-04-10
DOP2023000254A (es) 2023-12-29
US20240270750A1 (en) 2024-08-15
CA3219966A1 (en) 2022-12-01
AR125963A1 (es) 2023-08-30
ECSP23096182A (es) 2024-01-31
JOP20230303A1 (ar) 2023-11-23
MX2023013742A (es) 2023-11-28
WO2022251188A3 (en) 2023-01-05
AU2022283258A1 (en) 2024-01-04
KR20240013145A (ko) 2024-01-30
PE20250022A1 (es) 2025-01-07
CR20230597A (es) 2024-02-20
CL2023003503A1 (es) 2024-05-03
WO2022251188A8 (en) 2024-01-04
WO2022251188A2 (en) 2022-12-01
CO2023017975A2 (es) 2024-01-15
EP4346806A4 (en) 2025-07-23
CN117529315A (zh) 2024-02-06
TW202313625A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
SA522432955B1 (ar) Kras g12c مثبطات
JOP20250246A1 (ar) مثبطات kras
PH12021552482A1 (en) Compounds targeting prmt5
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
CR20200503A (es) Inhibidores de cinasa dependientes de ciclina
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
MX2022008487A (es) Degradadores de smarca2-vhl.
JOP20220228A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
EP4316504A3 (en) Compounds
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
SA523440367B1 (ar) مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1
EA202192760A1 (ru) Трициклические соединения
MX2024011755A (es) Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
JOP20230303A1 (ar) مثبطات كيناز alk2 تحتوي على إيميدازول
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
EA202192382A1 (ru) Соединения, нацеленные на prmt5
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7
MX2025006793A (es) Derivados de compuestos heterociclicos sustituidos y su uso farmaceutico
EA202092236A1 (ru) Производные 2-аминопиридина и 2-аминопиримидина в качестве ингибиторов циклинзависимых киназ
EA202190690A1 (ru) Борсодержащие ингибиторы pde4